Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sun Pharma shares tumble 4% as firm closes in on $12-billion Organon acquisition. What’s spooking investors?
Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & Co. Investors remain cautious as the pharma major nears its biggest-ever overseas acquisition amid debt concerns and volatile global conditions.
Sun Pharma preps for $12-billion Organon bid in biggest overseas pharma M&A by Indian co
Sun Pharma is moving forward with a $12 billion offer for Organon & Co. This acquisition would be the largest for an Indian pharma company. Sun Pharma is finalizing financing for the deal. Organon specializes in women's health. The company is also facing competition from other global consortiums. This move signifies Sun Pharma's ambition to grow in innovative drug research.
Sun Pharma closes in on Organon buy, gets set for $12 billion binding bid
Due diligence is complete, financing banks & advisors picked for biggest cross border pharma M&A by Indian pharma company. 2 other global suitors in fray.
Sun Pharmaceutical Industries Ltd eases for fifth straight session
Sun Pharmaceutical Industries Ltd is quoting at Rs 1689.8, down 0.22% on the day as on 13:19 IST on the NSE. The stock jumped 1.41% in last one year as compared to a 3.17% rally in NIFTY and a 8.74% spurt in the Nifty Pharma index.
Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocks
The US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. Sun Pharma faces the steepest risk, while CDMOs like Sai Lifesciences may see selective impact. Analysts at Jefferies and Nomura expect modest to mid-single-digit earnings pressure.
Sensex Today Trades Lower | Nifty Below 22,700 | Kotak Mahindra & Sun Pharma Top Losers - Equitymaster
Sensex Today Trades Lower | Nifty Below 22,700 | Kotak Mahindra & Sun Pharma Top LosersEquitymaster
US drug tariff risk limited for Indian pharma; Sun Pharma exposure in focus: Vishal Manchanda
According to Vishal Manchanda, Pharma Analyst, Systematix Group, potential US action on drug pricing is seen as focused on patented medicines, limiting direct impact on Indian generic manufacturers. Companies with higher exposure to specialty drugs may need to consider pricing agreements to avoid penalties. The expected earnings impact for affected firms remains contained. Sector dynamics continue to favour businesses with lower dependence on US generics, while policy developments and ongoing investigations remain key factors to monitor.
Nifty Pharma index drops 3% as US tariff fears hit Sun Pharma, peers
A Bloomberg report indicated that the Trump administration is planning tariffs on pharmaceutical companies that have not entered into agreements to ensure lower drug prices in the US.
Explained — Why Sun Pharma shares fell as much as 6% on Thursday
Sun Pharma is among the Indian companies with the highest exposure to branded pharmaceuticals.
Natco launches Rs 1,290 semaglutide in India, undercuts diabetes drug prices
Natco Pharma has launched a new generic semaglutide injection in India. This marks a significant step in making advanced diabetes treatment more accessible. The drug is available at a much lower price compared to existing options. This move is expected to benefit a large number of diabetic patients across the country.
IIT Roorkee inaugurates Ashok Soota Molecular Medicine Facility at BSBE to advance translational biomedical research
IIT Roorkee has launched the Ashok Soota Molecular Medicine Facility, a state-of-the-art platform for advanced biomedical research, drug discovery, and diagnostics. This integrated facility, equipped with advanced instrumentation, will accelerate translational research and contribute to national healthcare priorities and global scientific advancements.
